Study results were presented in Stockholm, leading to NMPA accepting the NDA for sovleplenib, using data from Peking Union Medical College Hospital.
1 report, 1 independent
Updated Jun 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Study results were presented in Stockholm, leading to NMPA accepting the NDA for sovleplenib, using data from Peking Union Medical College Hospital.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Jianming Xu is leading a study involving HUTCHMED (China) Limited.Sub-event
NMPA accepted NDA for sovleplenib, based on study data presented in Stockholm.1 source
Keep exploring
The entities involved
-
Peking Union Medical College Hospital
hospital in Beijing, China
Nothing else this week.